Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094255 | 0.91 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL21031325 | 0.82 | MAPT (0.53) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL24163381 | 0.80 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL15650739 | 0.80 | MEN1 (0.47) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL3401840 | 0.79 | HPGD (0.55) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL17774812 | 0.79 | HPGD (0.55) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL17774978 | 0.79 | HPGD (0.44) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL10126592 | 0.78 | HPGD (0.54) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL29451263 | 0.78 | HPGD (0.54) | L3MBTL3L3MBTL1HPGDGAAKMT2A | |
| SCHEMBL10126579 | 0.78 | HPGD (0.54) | L3MBTL3L3MBTL1HPGDGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-111655690-B | Pyrazolopyridinone compounds | 詹森药业有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019101182-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | FGFR1, FGFR3, FGFR2 | L3MBTL3 4705/4885L3MBTL1 4681/4885HPGD 1174/4885 |
| US-11691970-B2 | Pyrazolopyridinone compounds | FGFR1, FGFR3, FGFR2 | L3MBTL3 4705/4885L3MBTL1 4681/4885HPGD 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.